Radiotherapy Plus Cetuximab is Safe in a Head and Neck Cancer Patient on Immunosuppressants for Liver Transplant

Clinical Oncology

Volumn 19, Issue 5, 2007, Pages 365-366

  Mydin, A R ^a   Armstrong, J G ^a  

^a ST LUKE S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ADULT; ALCOHOL LIVER CIRRHOSIS; ASPIRATION BIOPSY; CANCER LOCALIZATION; CANCER SIZE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOSCOPIC SURGERY; FOLLOW UP; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LETTER; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; METASTASIS POTENTIAL; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 34249040322     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2007.02.011     Document Type: Letter

References (2)

1. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
2. US Food and Drug Administration, Center for Drug Evaluation and Research. Listing of approved oncology drugs with approved indications (2006). http://www.fda.gov/cder/foi/label/2006/125084s46lbl.pdf